News
23andMe to Report Fourth Quarter and Fiscal Year 2024 Financial Results
23andMe, Inc.
SOUTH SAN FRANCISCO, Calif., May 9, 2024 (GLOBE NEWSWIRE) — 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people access, understand and to benefit from the human genome, announced today that it will report fourth quarter and full fiscal year 2024 (FY 2024) financial results after the market closes on Thursday, May 23, 2024. The company will broadcast a web conference call at 4:30 pm ET on that date to discuss quarterly and full-year financial results and report on business progress.
The webcast can be accessed on the day of the event at https://investors.23andme.com/news-events/events-presentations. A replay of the webcast will be available at the same address after the event. Additionally, 23andMe will use the Say Technologies platform to allow institutional and retail shareholders to submit and upvote management ahead of the earnings call. Starting today, shareholders can submit questions by visiting https://app.saytechnologies.com/23andme-2024-q4. The Q&A platform will remain open up to 24 business hours before the earnings call.
About 23andMe
23andMe is a genetics-led consumer healthcare and therapeutics company that powers a healthier future. For more information please visit investors.23andme.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, without limitation, statements regarding the future performance of 23andMe . business in consumer genetics and therapeutics and the growth and potential of its proprietary research platform. All statements, other than statements of historical fact, included or incorporated into this press release, including statements regarding 23andMe’s strategy, financial position, financial projections, financing for continued operations, cash reserves, projected costs, database growth, management plans and objectives, are forward-looking statements. The words “believe”, “anticipate”, “estimate”, “plan”, “expect”, “intend”, “may”, “could”, “should”, “potential”, “likely”, “project”, “anticipates”, “continues”, “will”, “schedule” and “would” or, in each case, negative variations thereof or other variations or comparable terminology, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements are predictions based on 23andMe’s current expectations and projections about future events and various assumptions. 23andMe cannot guarantee that it will actually achieve the plans, intentions or expectations disclosed in its forward-looking statements and you should not place undue reliance on 23andMe’s forward-looking statements. These forward-looking statements involve a number of risks, uncertainties (many of which are beyond 23andMe’s control) or other assumptions that could cause actual results or performance to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements contained herein are also generally subject to other risks and uncertainties that are described from time to time in the Company’s filings with the Securities and Exchange Commission, including in Item 1A, “Risk Factors” in the Company’s most recent Annual Report. on Form 10-K, as filed with the Securities and Exchange Commission, and as reviewed and updated by our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The statements made here are made as of the date of this press release and, except as required by law, 23andMe undertakes no obligation to update them, whether as a result of new information, developments or otherwise.
The story continues
Contacts
Investor Relations Contact: Ian Cooney, ianc@23andme.com
Media Contact: press@23andMe.com
